In other words if Big Pharma has their eye on an acquisition, there’s no time like the present. Takeover target are cheaper now than they have been in years.
“And Big Pharma doesn’t need as much financing because they have so much cash, so the deals should be more likely to get done,” adds Finerman.
What's the trade?
Finerman does not recommend stock picking in this space. “I can’t evaluate each drug at each drug company,” she says. That’s too complicated.
So she recommends gaming the space with ETF’s; either the SPDR S&P Biotech or the iShares NASDAQ Biotechnology Index .
Both, she says, should move in sympathy if and when a deal happens.
Got something to to say? Send us an e-mail at email@example.com and your comment might be posted on the Rapid Recap. If you'd prefer to make a comment but not have it published on our website send those e-mails to firstname.lastname@example.org.
CNBC.com with wires